South and Central America Neurological Biomarker Market to Grow at a CAGR of 11.5% to reach US$ 1,185.28 million from 2020 to 2027

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. South and Central America Neurological Biomarker Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. South and Central America Neurological Biomarker Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1
5.1.2 Rising incidences of neurological diseases
5.1.3 Rapid Developments in healthcare

5.2 Market Opportunities

5.2.1
5.2.2 Development of novel biomarkers
5.2.3 Integration of drug development and biomarkers
5.2.4 Focus on early detection and prevention

5.3 Future Trends

5.3.1
5.3.2 Advancement in biomarker discovery
5.3.3 increased focus on personalized medicines

5.4 Impact of Drivers and Restraints

6. South and Central America Neurological Biomarker Market Regional Analysis

6.1 South and Central America Neurological Biomarker Market Overview

6.2 South and Central America Neurological Biomarker Market Revenue 2017-2027 (US$ Million)

6.3 South and Central America Neurological Biomarker Market Forecast Analysis

7. South and Central America Neurological Biomarker Market Analysis – by Product

7.1 Proteomics Biomarker

7.1.1 Overview
7.1.2 Proteomics Biomarker: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Genomics Biomarker

7.2.1 Overview
7.2.2 Genomics Biomarker: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Metabolomics Biomarker

7.3.1 Overview
7.3.2 Metabolomics Biomarker: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Imaging Biomarker

7.4.1 Overview
7.4.2 Imaging Biomarker: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2031 (US$ Million)

8. South and Central America Neurological Biomarker Market Analysis – by Application

8.1 Alzheimer's Disease

8.1.1 Overview
8.1.2 Alzheimer's Disease: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

8.2 Parkinson's Disease

8.2.1 Overview
8.2.2 Parkinson's Disease: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

8.3 Schizophrenia

8.3.1 Overview
8.3.2 Schizophrenia: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

8.4 Huntington's Disease

8.4.1 Overview
8.4.2 Huntington's Disease: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

8.5 Spinal Muscular Atrophy

8.5.1 Overview
8.5.2 Spinal Muscular Atrophy: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

9. South and Central America Neurological Biomarker Market Analysis – by End User

9.1 Pharmaceutical and Biotechnology Companies

9.1.1 Overview
9.1.2 Spinal Muscular Atrophy: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

9.2 Clinical Diagnostics

9.2.1 Overview
9.2.2 Spinal Muscular Atrophy: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

9.3 Research Organizations

9.3.1 Overview
9.3.2 Spinal Muscular Atrophy: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

10. South and Central America Neurological Biomarker Market – South and Central America Analysis

10.1 South and Central America

10.1.1 South and Central America Neurological Biomarker Market Breakdown, by Key Country, 2020 and 2027 (%)
10.1.1.1 South and Central America Neurological Biomarker Market – Revenue and Forecast Analysis – by Country
10.1.1.1 Brazil: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.1.1 Brazil: South and Central America Neurological Biomarker Market Breakdown, by Product
10.1.1.1.2 Brazil: South and Central America Neurological Biomarker Market Breakdown, by Application
10.1.1.1.3 Brazil: South and Central America Neurological Biomarker Market Breakdown, by End User

10.1.1.2 Argentina: South and Central America Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.2.1 Argentina: South and Central America Neurological Biomarker Market Breakdown, by Product
10.1.1.2.2 Argentina: South and Central America Neurological Biomarker Market Breakdown, by Application
10.1.1.2.3 Argentina: South and Central America Neurological Biomarker Market Breakdown, by End User

10.1.1.3 Rest of South and Central America : South and Central America Neurological Biomarker Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.3.1 Rest of South and Central America : South and Central America Neurological Biomarker Market Breakdown, by Product
10.1.1.3.2 Rest of South and Central America : South and Central America Neurological Biomarker Market Breakdown, by Application
10.1.1.3.3 Rest of South and Central America : South and Central America Neurological Biomarker Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. South and Central America Neurological Biomarker Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Thermo Fisher Scientific Inc.

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Abbott

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Bio-Rad Laboratories Inc.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 QIAGEN

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Immunarray Pvt. Ltd.

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Quest Diagnostics Incorporated

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Perkin Elmer, Inc

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 MERCK KGaA

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights